AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
Feb. 19, 2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

Featured image for “Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma”
Feb. 05, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Featured image for “Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up”
Jan. 23, 2026

Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up

Featured image for “Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026”
Jan. 21, 2026

Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026

Featured image for “The Integrative Care Approach”
Jan. 13, 2026

The Integrative Care Approach

Filter by Tag